Your session is about to expire
← Back to Search
Levonorgestrel plus meloxicam for Birth Control
Study Summary
This trial aims to see if a combination of two medications, levonorgestrel and meloxicam, can delay ovulation in obese women with normal menstrual cycles compared to a placebo. Participants will
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are individuals older than twenty years of age eligible to participate in this clinical trial?
"The trial is seeking individuals above 18 years and under 40 years of age to participate."
What is the total number of participants being recruited for this clinical investigation?
"Indeed, the details on clinicaltrials.gov affirm that this research study is actively seeking suitable candidates. The trial was initially shared on December 10th, 2023 and last modified on March 8th, 2024. There is a need to enroll 22 participants at one designated site."
Which specific criteria must individuals meet in order to be eligible for participation in this medical study?
"Candidates seeking entry into this research study must meet the criteria of utilizing contraception methods and falling within the age bracket of 18 to 40 years old. The trial aims to enroll approximately 22 eligible participants."
Are there any ongoing efforts to enroll patients in this clinical trial?
"As indicated on clinicaltrials.gov, patient recruitment for this trial is currently ongoing. The trial was initially listed on 12th October 2023 and last revised on 8th March 2024."
Has the combination of Levonorgestrel and meloxicam received approval from the FDA?
"The safety assessment of the combination Levonorgestrel and meloxicam has been rated as 2 by our team at Power, based on it being a Phase 2 trial. This rating suggests that there is existing safety data available but no evidence supporting its efficacy yet."
Share this study with friends
Copy Link
Messenger